News

Shares of Ardelyx (NASDAQ: ARDX) were down more than 12% as of 3:30 p.m. on Wednesday. The healthcare company, which has a chronic kidney disease (CKD) drug that is awaiting approval later this

Medical device giant Abbott Laboratories (NYSE: ABT) hasn't performed well in the past year. The company has had to deal with several issues that affected its results and its public image, notably

Despite strong gains for the broader market this year, AT&T (NYSE: T) stock continues to struggle. The company's share price is down nearly 19% so far in 2023. With the stock trading at low earnings

Intellia Therapeutics (NASDAQ: NTLA) has announced a good deal of positive news in recent months, from progress in clinical trials to an expanded partnership with big biotech Regeneron

Gene-editing specialist Intellia Therapeutics (NASDAQ: NTLA) has caught the attention of Cathie Wood. The founder and CEO of Ark Invest, an investment management firm focused on investing in

Shares of Scilex Holdings (NASDAQ: SCLX) were up around 14% as of 2:30 p.m. ET on Monday. The healthcare stock is still down more than 55% this year.

Scilex makes non-opioid pain management products

Shares of Tango Therapeutics (NASDAQ: TNGX) were down more than 12% as of 11:15 a.m. on Monday. The healthcare stock is up more than 37% this year.

Tango is a clinical-stage biotech that focuses on

The stock market has rendered its verdict on AT&T (NYSE: T) stock this year. While the S&P 500 is up around 10% year-to-date, shares of the telecom giant have tumbled roughly 20%.

There are some

Cathie Wood manages net assets of around $12 billion in her Ark Invest exchange-traded funds (ETFs). It's part of her job to keep close tabs on macroeconomic trends while also focusing on major

Gene editing is one of the most revolutionary trends in modern medicine. The potential to swap out a person's genes to eliminate and prevent diseases is here, and investors are keenly looking at

Smart investors are continually looking for new investment ideas. Sometimes, those ideas are so good that they're hard to pass up.

Three Motley Fool contributors think they've picked some stocks

Early on in the pandemic, Moderna and Pfizer beat smaller rival Novavax (NASDAQ: NVAX) to market with their coronavirus vaccines by a year or more in some countries. This head start offered them the

Shares of AT&T (NYSE: T) fell as much as 6% early Friday, then settled to close down around 2.7% following a report that the company is weighing whether to divest its stake in DirecTV next year.

There are excellent reasons to invest in dividend stocks beyond their regular payouts. Growing a dividend requires companies to deliver solid financial results regularly, and the longer a

Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) are two top pharmaceutical companies that are pursuing growth opportunities. Pfizer is looking to build up and diversify its business as its COVID

For dividend investors, AT&T (NYSE: T) stock may seem like one of the best options simply because of its tantalizing 7.4% dividend yield. However, there is more to a company than just how much of a

Shares of Coherus BioSciences (NASDAQ: CHRS) rose 9.4% on Thursday after the biotech resubmitted a biologic license application (BLA) supplement for a key product to the U.S. Food and Drug

Shares of uniQure (NASDAQ: QURE) were up more than 8% as of 1 p.m. after rising as much as 14% earlier in the day. So far this year, the biotech stock is down more than 70%.

The gene-editing therapy

Investing wisdom tells us to buy low, but what exactly constitutes a "low" point? Consider the case of Regeneron (NASDAQ: REGN), a biotech company that has beaten the market in recent years. Despite